✦ LIBER ✦

Arsenic trioxide as a treatment for myelodysplastic syndrome

✍ Scribed by Mikkael A Sekeres

Book ID: 107540141
Publisher: Current Science Inc.
Year: 2006
Tongue: English
Weight: 209 KB
Volume: 1
Category: Article
ISSN: 1558-8211
DOI: 10.1007/s11899-006-0015-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Opportunities for Trisenox® (arsenic tri

Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes

✍ List, A; Beran, M; DiPersio, J; Slack, J; Vey, N; Rosenfeld, C S; Greenberg, P 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 202 KB

Differentiation syndrome with lethal lun

Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome

✍ Yishay Ofran; Irit Avivi; Benjamin Gesundheit; Reuven Or; Jacob M. Rowe; Tsila Z 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB

Haem arginate as a treatment for myelody

Haem arginate as a treatment for myelodysplastic syndromes

✍ Tapani Ruutu; Liisa Volin; Raimo Tenhunen 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

Acute lung injury induced by arsenic tri

Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome

✍ Hesham A. Hassaballa; Omar B. Lateef; Michael R. Silver; Robert A. Balk 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 119 KB

Arsenic intoxication presenting as a mye

Arsenic intoxication presenting as a myelodysplastic syndrome: A case report

✍ William N. Rezuke; Crawford Anderson; William T. Pastuszak; Stephen R. Conway; S 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

Combination decitabine, arsenic trioxide

Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study

✍ John S. Welch; Jeffery M. Klco; Feng Gao; Elizabeth Procknow; Geoffery L. Uy; Ke 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 774 KB

Childhood immune thrombocytopenia (ITP) has a favorable outcome in most cases but severe bleeding may occur, mostly in children with very low platelet counts. Although first-line therapies are well defined, management of refractory ITP is not consensual. Vinblastine (VBL) is one second-line treatmen